The possible role of the kynurenine pathway in adolescent depression with melancholic features.
BACKGROUND
Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups. This study addresses this issue by examining whether adolescent MDD with and without melancholic features (M-MDD and NonM-MDD) have distinct biological features in the kynurenine pathway (KP). The KP is initiated by pro-inflammatory cytokines via induction of the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan (TRP) into kynurenine (KYN). KYN is further metabolized into neurotoxins linked to neuronal dysfunction in MDD. Hypotheses were that, compared to healthy controls and to NonM-MDD adolescents, adolescents with M-MDD would exhibit: (i) increased activation of the KP [i.e., increased KYN and KYN/TRP (reflecting IDO activity)]; (ii) greater neurotoxic loads [i.e., increased 3-hydroxyanthranilic acid (3-HAA, neurotoxin) and 3-HAA/KYN (reflecting production of neurotoxins)]; and (iii) decreased TRP. We also examined relationships between severity of MDD and KP metabolites.


METHODS
Subjects were 20 adolescents with M-MDD, 30 adolescents with NonM-MDD, and 22 healthy adolescents. MDD episode duration had to be >or= 6 weeks and Children's Depression Rating Scale-Revised (CDRS-R) scores were >or= 36. Blood samples were collected at AM after an overnight fast and analyzed using high-performance liquid chromatography. Group contrasts relied on analysis of covariance based on ranks, adjusted for age, gender, and CDRS-R scores. Analyses were repeated excluding medicated patients. Fisher's protected least significant difference was used for multiple comparisons.


RESULTS
As hypothesized, KYN/TRP ratios were elevated and TRP concentrations were reduced in adolescents with M-MDD compared to NonM-MDD adolescents (p = .001 and .006, respectively) and to healthy controls (p = .008 and .022, respectively). These findings remained significant when medicated patients were excluded from the analyses. Significant correlations were obtained exclusively in the M-MDD group between KYN and 3-HAA/KYN and CDRS-R.


CONCLUSIONS
Findings support the notion that adolescent M-MDD may represent a biologically distinct clinical syndrome.
Gabbay
Vilma
V
NYU Child Study Center, Child and Adolescent Psychiatry, New York University School of Medicine, NY 10016, USA. vilma.gabbay@nyumc.org
Klein
Rachel G
RG
Katz
Yisrael
Y
Mendoza
Sandra
S
Guttman
Leah E
LE
Alonso
Carmen M
CM
Babb
James S
JS
Hirsch
Glenn S
GS
Liebes
Leonard
L
D015095:3-Hydroxyanthranilic Acid / Q000378:metabolism; D000293:Adolescent; D002648:Child; D016207:Cytokines / Q000097:blood; D003866:Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology* / Q000523:psychology; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology* / Q000523:psychology; D004790:Enzyme Induction; D005260:Female; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000097:blood; D018836:Inflammation Mediators / Q000097:blood; D007737:Kynurenine / Q000097:blood*; D008297:Male; D009498:Neurotoxins / Q000097:blood; D012016:Reference Values; D014364:Tryptophan / Q000097:blood; D055815:Young Adult
D016207:Cytokines; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D018836:Inflammation Mediators; D009498:Neurotoxins; D015095:3-Hydroxyanthranilic Acid; D007737:Kynurenine; D014364:Tryptophan
J Psychiatr Res. 2002 Jul-Aug;36(4):247-56
12191629
J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1427-39
17135988
J Psychopharmacol. 2010 Jun;24(6):809-15
19074538
J Affect Disord. 2007 Feb;98(1-2):143-51
16952400
Arch Gen Psychiatry. 1987 Oct;44(10):854-61
3662742
Arch Gen Psychiatry. 2004 Jul;61(7):705-13
15237082
Mol Psychiatry. 2002;7(5):468-73
12082564
Psychiatry Res. 1994 Nov;54(2):143-60
7761549
Mol Psychiatry. 2005 Jun;10(6):538-44
15494706
Psychoneuroendocrinology. 2001 Nov;26(8):797-808
11585680
Biol Psychiatry. 1992 Aug 15;32(4):354-63
1420649
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):37-44
19778568
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
9204677
Brain Behav Immun. 2007 May;21(4):374-83
17360153
Biol Psychiatry. 2003 Nov 1;54(9):906-14
14573318
Arch Gen Psychiatry. 1974 Oct;31(4):447-54
4420562
J Affect Disord. 1989 Jan-Feb;16(1):27-31
2521647
J Affect Disord. 2009 May;115(1-2):177-82
18790541
Mol Psychiatry. 2001 Jul;6(4):475-80
11443537
Exp Neurol. 2006 Jan;197(1):31-40
16099455
Psychiatry Res. 1987 Aug;21(4):323-35
3628615
Biochemistry. 2000 Jun 20;39(24):7266-75
10852726
J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7
6715741
Neuropsychopharmacology. 1996 Sep;15(3):243-51
8873107
Am J Psychiatry. 1994 Apr;151(4):489-98
8147445
Science. 1983 Jan 21;219(4582):316-8
6849138
J Affect Disord. 1990 Nov;20(3):185-91
2148339
Eur Child Adolesc Psychiatry. 1996 Sep;5(3):155-61
8908422
J Affect Disord. 1989 Sep-Oct;17(2):99-104
2527896
Psychol Med. 1991 Aug;21(3):613-8
1719577
J Neurol Neurosurg Psychiatry. 1970 Oct;33(5):698-704
5478953
Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
6639293
Am J Clin Nutr. 1989 Jul;50(1):46-52
2750695
Br J Psychiatry Suppl. 1991 Jul;(11):9-21
1840758